Which company does Pemigatinib come from?

Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has approved pemigatinib, a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangements. Pemetinib has previously been approved for the treatment of adult patients with cholangiocarcinoma that has spread to other parts of the body (metastatic) or cannot be removed by surgery. Incyte is headquartered in the United States.

Pemetinib is a drug that uses genetic testing on tumor tissue to determine whether a patient is suitable for treatment. If a patient has a FGFR2 gene mutation in cholangiocarcinoma, pemetinib may be used as part of the treatment plan. Pemigatinib, the active ingredient in Pemigatinib, blocks the abnormal activation of cell signal transduction pathways by inhibiting the FGFR protein in tumor cells, thereby reducing the proliferation and viability of tumor cells. It may also cause some adverse reactions, including nausea, vomiting, fatigue, high blood pressure, etc.

The original drug of pemetinib has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. The price of each box of 4.5mg*14 tablets may be around 30,000 yuan, which is expensive. The price of the original pemetinib drug, 13.5mg*14 tablets, per box sold overseas may be around RMB 70,000 (the price may fluctuate due to exchange rates). There are also generic pemetinib drugs produced in other countries overseas. For example, the price of a box of 4.5mg*21 tablets produced by a Laos pharmaceutical factory may be around 3,000 yuan (the price may fluctuate due to the exchange rate). The price is relatively cheap. The pharmaceutical ingredients of the generic drugs are basically the same as those of the original drugs at home and abroad.